Literature DB >> 1833169

Costs of temporary and permanent disability induced by diabetes.

E M Olivera1, E P Duhalde, J J Gagliardino.   

Abstract

OBJECTIVE: To evaluate the indirect costs of diabetes and show their relationship to the chronic complications of diabetes. RESEARCH DESIGN AND METHODS: The cost of temporary and permanent disability for diabetic patients was studied in a group of La Plata University employees and in a second group at the government institutions of the Buenos Aires Province during 3 consecutive yr (1984-1986).
RESULTS: Absences due to temporary disability were similar for the diabetic group without chronic complications and an age- and sex-matched nondiabetic control group. Conversely, diabetic patients with chronic complications had major increases in absences compared with the control subjects. Diabetes mellitus was the third leading cause of permanent disability mainly due to macrovascular and retinal lesions. This disability resulted in an average of 11 yr of work production loss per patient.
CONCLUSIONS: These results suggest that diabetic individuals without complications incur few additional costs compared with nondiabetic individuals. However, once complications appear, the indirect costs are very high, suggesting that secondary preventions of the diabetic complications might be an optimal approach for reducing the health-care burden of diabetes.

Entities:  

Mesh:

Year:  1991        PMID: 1833169     DOI: 10.2337/diacare.14.7.593

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 2.  Global healthcare financing for type II diabetes: are there ways out of the crisis?

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

Review 3.  Costs of insulin-dependent diabetes mellitus.

Authors:  T T Simell; H Sintonen; J Hahl; O G Simell
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 4.  Diabetes mellitus and the St Vincent Declaration. The economic implications.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

5.  Reductions in individual work productivity associated with type 2 diabetes mellitus.

Authors:  Jill E Lavigne; Charles E Phelps; Alvin Mushlin; Wayne M Lednar
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients.

Authors:  M I Domenech; D Assad; M E Mazzei; P Kronsbein; J J Gagliardino
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

7.  Direct costs associated with chronic kidney disease among type 2 diabetic patients in India.

Authors:  K Satyavani; H Kothandan; M Jayaraman; V Viswanathan
Journal:  Indian J Nephrol       Date:  2014-05

8.  Survival rates and worker compensation expenses in a national cohort of Mexican workers with permanent occupational disability caused by diabetes.

Authors:  Iván de Jesús Ascencio-Montiel; Jesús Kumate-Rodríguez; Víctor Hugo Borja-Aburto; José Esteban Fernández-Garate; Selene Konik-Comonfort; Oliver Macías-Pérez; Ángel Campos-Hernández; Héctor Rodríguez-Vázquez; Verónica Miriam López-Roldán; Edgar Jesús Zitle-García; María Del Carmen Solís-Cruz; Ismael Velázquez-Ramírez; Miriam Aguilar-Jiménez; Leonel Villa-Caballero; Nelly Cisneros-González
Journal:  BMC Public Health       Date:  2016-09-01       Impact factor: 3.295

9.  Pharmacoeconomic evaluation of diabetic nephropathic patients attending nephrology department in a tertiary care hospital.

Authors:  J V Jose; M Jose; P Devi; R Satish
Journal:  J Postgrad Med       Date:  2017 Jan-Mar       Impact factor: 1.476

Review 10.  Diabetes in Argentina: cost and management of diabetes and its complications and challenges for health policy.

Authors:  Joaquín E Caporale; Jorge F Elgart; Juan J Gagliardino
Journal:  Global Health       Date:  2013-10-29       Impact factor: 4.185

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.